 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Christopher Lieu and Bradley Corr.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.172 |
|
|
|
-
Alsafar A, Kareem SL, Corr BR, Lieu CH, Wilky B, Davis SL, Camidge DR, Jimeno A, Messersmith WA, Nicklawsky A, Pacheco D, Borrayo EA, McDermott JD, Diamond JR. Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center. Front Oncol. 2025; 15:1546500.
Score: 0.061
-
Davis SL, Messersmith WA, Purcell WT, Lam ET, Corr BR, Leal AD, Lieu CH, O'Bryant CL, Smoots SG, Dus ED, Jordan KR, Serkova NJ, Pitts TM, Diamond JR. A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors. Cancers (Basel). 2024 Apr 10; 16(8).
Score: 0.056
-
Schreiber AR, Kagihara JA, Corr BR, Davis SL, Lieu C, Kim SS, Jimeno A, Camidge DR, Williams J, Heim AM, Martin A, DeMattei JA, Holay N, Triplett TA, Eckhardt SG, Litwiler K, Winkler J, Piscopio AD, Diamond JR. First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors. Cancers (Basel). 2023 Dec 23; 16(1).
Score: 0.055
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|